产品
编 号：F023498
分子式：C35H34ClN7O3S2
分子量：700.27
分子式：C35H34ClN7O3S2
分子量：700.27
产品类型
规格
价格
是否有货
结构图
CAS No: 1056164-52-3
产品详情
生物活性：
PF-03715455 is a potent inhaled p38 MAPK inhibitor. PF-03715455 shows some selectivity for p38α over p38β with respective IC50 values of 0.88 and 23 nM. PF-03715455 potently inhibits LPS-induced TNFα production in human whole blood (IC50=1.7 nM). PF-03715455 has potential for the treatment of COPD (chronic obstructive pulmonary disease).
体内研究：
PF-03715455 treatment shows that the Vss and T1/2 are 0.19 L/kg, 1 hour, respectively.Animal Model:Male CD Sprague Dawley rats (300-450 g)
Dosage:1 mg/kg
Administration:I.v. (Pharmacokinetic Analysis)
Result:The Vss, and T1/2 were 0.19 L/kg, 1 hour, respectively.
体外研究：
PF-03715455 is a moderate inhibitor of CYP1A2, CYP2C19, and CYP2D6 and a potent inhibitor of CYP’s 2C9 and CYP3A4.
PF-03715455 is a potent inhaled p38 MAPK inhibitor. PF-03715455 shows some selectivity for p38α over p38β with respective IC50 values of 0.88 and 23 nM. PF-03715455 potently inhibits LPS-induced TNFα production in human whole blood (IC50=1.7 nM). PF-03715455 has potential for the treatment of COPD (chronic obstructive pulmonary disease).
体内研究：
PF-03715455 treatment shows that the Vss and T1/2 are 0.19 L/kg, 1 hour, respectively.Animal Model:Male CD Sprague Dawley rats (300-450 g)
Dosage:1 mg/kg
Administration:I.v. (Pharmacokinetic Analysis)
Result:The Vss, and T1/2 were 0.19 L/kg, 1 hour, respectively.
体外研究：
PF-03715455 is a moderate inhibitor of CYP1A2, CYP2C19, and CYP2D6 and a potent inhibitor of CYP’s 2C9 and CYP3A4.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备